Case Report

The Foot That Broke Both Hips: A Case Report and Literature Review of Tumor-Induced Osteomalacia

Sara Beygi, 1 Alfred Denio, 2 and Tarun S. Sharma 3

1 Internal Medicine Department, Allegheny Health Network, Pittsburgh, PA, USA
2 Rheumatology Department, Geisinger Medical Center, Danville, PA, USA
3 Rheumatology Department, Allegheny Health Network, Pittsburgh, PA, USA

Correspondence should be addressed to Tarun S. Sharma; tsharma@wpahs.org

Received 18 February 2017; Revised 20 June 2017; Accepted 4 July 2017; Published 14 September 2017

Academic Editor: Remzi Cevik

Copyright © 2017 Sara Beygi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by hypophosphatemia and clinical symptoms of osteomalacia. Only discussed as case reports, there is still limited knowledge of this condition as a potentially curable cause of osteomalacia among clinicians and pathologists. In this article, we present a case of tumor-induced osteomalacia in a 59-year-old gentleman followed by an up-to-date review of the existing literature on TIO.

1. Introduction

Tumor-induced osteomalacia (TIO) or oncogenic osteomalacia is an underrecognized paraneoplastic syndrome presenting with hypophosphatemia and typical manifestations of osteomalacia [1]. The clinical syndrome of osteomalacia and associated biochemical abnormalities including low phosphate and 1,25-dihydroxyvitamin D levels are blamed on the production of phosphate-regulating substances, most notably fibroblast growth factor 23 (FGF23), by tumor cells [2, 3]. Since the FGF23-producing tumors tend to be small and hard to detect on physical exam, symptoms of osteomalacia, including bone pain and muscle weakness, sometimes precede the diagnosis of the tumor by years. The fact that surgical resection of the tumor is usually curative highlights the importance of raising awareness of this condition among clinicians and pathologists.

In this article, we present a case of TIO followed by a review of the current literature.

2. Case Presentation

A 59-year-old gentleman was hospitalized in May 2013 for elective repair of a stress fracture of the medial midshaft of the right femur. Orthopedic surgeons planned to perform an elective surgery. A routine rheumatology consult as part of the fracture liaison service was requested. Upon further questioning, he admitted to a minor fall while carrying a heating unit up a flight of stairs a few months prior to admission. Since then, he had persistent discomfort in the right thigh and was complaining of difficulty walking, loss of balance, and leg “giving out on him” for a few months. His past medical history was only remarkable for hypertension and cervical spinal stenosis, and his social/family history was noncontributory.

Physical examination revealed a man of normal stature with normal-appearing limbs. He had tenderness to palpation of the right medial midthigh region. In addition, some mild tenderness in the left midthigh was noted. The remainder of the exam including testicles, sclera, and skin elasticity was unremarkable.

Preoperative workup included an AP pelvis X-ray which revealed a left subtrochanteric femur stress fracture in addition to the known right femur fracture (Figure 1). An intramedullary device was placed bilaterally.

Laboratory parameters obtained prior to surgery are as follows:

(i) Calcium: 9.4 mg/dL (n: 8.3–10.5)
(ii) Alkaline phosphatase: 135 U/L (n: 0–153)
(iii) 25-Hydroxyvitamin D level: 22 ng/mL (n: 30–100)
(iv) 24-hour urine calcium: 0.223 g/24 hours (n: 0.05–0.3)
(v) TSH: 2.24 uIU/mL (n: 0.27–4.2)
(vi) Creatinine: 1.0 mg/dL (n: 0.7–1.5)
(vii) iPTH: 50 pg/mL (n: 10–65)
(viii) Phosphate: 1.5 mg/dL (n: 2.5–4.8)
(ix) 24-hour urine phosphate: 0.821 g/24 hours (n: 0.3–1)
(x) Plasma fibroblast growth factor 23 (FGF23): 211 RU/mL (n < 180)

An iliac crest bone biopsy with trichrome staining (Figure 2) and tetracycline labeling (Figure 3) revealed marked osteomalacia and a severe mineralization defect.

A whole body PET/CT revealed uptake within a soft tissue nodule in the plantar surface of the left foot, at the level of the 2nd and 3rd metatarsophalangeal joints (Figure 4).

Excisional biopsy of the left plantar foot nodule revealed a benign mesenchymal tumor consisting of small vessels admixed with fibrocartilage foci (Figures 5–7).

The tumor was resected, and the patient’s FGF23 and phosphate levels returned to normal soon after the surgery (phosphate: 4.6 mg/dL day 11 post-op, FGF23: 76 RU/mL 4 months post-op). The patient has been following up with an orthopedic oncologist every 6 months. The FGF23 and phosphate values continue to be within normal limits during the follow-up period, and the patient remains asymptomatic with no indications of recurrence (phosphate: 2.8 mg/dL, FGF23: 83 RU/mL at 14-month follow-up).
3. Literature Review Method

A PubMed search was performed on January 1, 2017, using the following search strategy:

(((oncogenic osteomalacia[Title/Abstract]) OR oncogenic hypophosphatemia[Title/Abstract]) OR tumor induced osteomalacia[Title/Abstract]) OR tumor induced hypophosphatemia[Title/Abstract]) OR tumor-induced hypophosphatemia[Title/Abstract]) OR tumor-induced osteomalacia[Title/Abstract]) OR phosphaturic mesenchymal tumor[Title/Abstract].

A total of 490 articles were retrieved and reviewed.

4. Background

For the first time in 1947, McCance reported a 15-year-old patient with weakness, gait disturbances, and low phosphate level whose symptoms completely resolved after resection of a tumor found in her femur [4]. However, her condition was inaccurately attributed to vitamin D resistance. As it is inferred from the literature, back in those days vitamin D resistance was believed to be the mechanism of what was eventually recognized as FGF23-induced phosphate-wasting disorder [5]. The first person who blamed the disease on the production of a "rachitogenic" substance by tumor cells was Prader [6]. He described severe rickets in an 11-year-old girl who was found to have a giant cell granuloma of the rib. Complete resolution of her rickets was achieved following resection of the tumor. Prader clearly delineated the association between resolution of the symptoms and tumor resection and proposed that the granuloma might have released a rachitogenic mediator. Since recognition of the condition, around 350 cases have been reported in the literature, most of them being published over the last 10 years.

It was repeatedly noted by different experts that TIO-associated tumors share distinctive morphological features, favoring an unidentified histopathological entity [7]. The term "phosphaturic mesenchymal tumor" (PMT) was introduced by Weidner and Santa Cruz [8], and PMT was eventually added to the 2013 WHO classification of tumors of the soft tissue and bone [9].

5. Clinical Characteristics

Tumor-induced osteomalacia typically occurs in adults, with equal gender distribution [10]. Patients usually present with progressive musculoskeletal symptoms including pain, proximal muscle weakness, and fractures. Due to general unawareness of this condition, there is usually a significant lag between the onset of symptoms and diagnosis. Therefore, it is not uncommon for patients to present with multiple fractures occasionally leading to height loss and a debilitated state [11].

The classic biochemical profile is characterized by normal calcium and parathormone levels, low or inappropriately normal 1,25-dihydroxyvitamin D levels, and elevated alkaline phosphatase levels [12].

Differentiating TIO from acquired and hereditary disorders that could present with hypophosphatemic osteomalacia would be of paramount importance. The acquired causes include nutritional deficiencies of vitamin D or phosphate as well as renal tubular abnormalities due to a variety of causes such as burns, heavy metal exposure, certain medications, and paraproteinemia [1, 13]. The inherited causes of hypophosphatemic osteomalacia include X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR), and hereditary hypophosphatemic rickets with hypercalciuria (HHRH) which are biochemical equivalents of TIO with high or inappropriately normal levels of FGF23 [1, 13].
Phosphaturic mesenchymal tumors tend to be small and not easily detectable on physical exam [10]. In fact, it is the osteomalacia and associated metabolic abnormalities which usually raise suspicion for an underlying tumor. TIO has been reported in association with other types of tumors as well, most notably small cell carcinoma and neurofibromatosis [14], although this is usually a feature of PMTs. However, unlike PMTs, in the case of TIO associated with other tumors, the primary tumor is usually known at the time of presentation. This type of presentation is sometimes referred to as secondary TIO [13]. Interestingly, few cases of TIO secondary to colon adenocarcinoma and ovarian cancer have also been reported [15, 16].

Reviewing the reported cases of TIO to date reveals that 50–55% of the tumors have been reported to arise from soft tissues and 40–45% in bones. Thigh and femur tend to be the most common anatomical sites (22.7%), followed by the craniofacial region (20.7%), ankle and foot (8.8%), pelvis (8.2%), tibia and fibula (6.5%), and arms (6.5%) [17]. In the head and neck region, three-fourths of the cases were noted in extraoral sites, with paranasal sinuses being the most common location [10]. There has not been a single report of the retroperitoneum or parenchymal organ as the primary site of the tumor [18].

6. Histopathological Features

The classic histological appearance of phosphaturic mesenchymal tumors consists of a background of spindle- to stellate-shaped neoplastic cells with a "smudgy" appearance which are generally normochromic with small nuclei and indistinct nucleoli [1]. The nuclear grade and mitotic activity are characteristically low. The cells are typically nested within a myxochondroid matrix with so-called "grungy" calcifications resembling the cartilage or osteoid tissue. Osteoclast-appearing giant cells are a common finding while mature lamellar bone may also be noted. A prominent feature of these tumors is an elaborate microvascular network with vessels of various sizes and patterns resembling a "staghorn" [13]. Microcystic changes have also been frequently described. Lately, immunostaining with D2-40, an antibody against a lymphatic marker, has proven to be positive in analysis of the fluids from microcysts, suggesting a partial differentiation toward lymphatic endothelial cells [19]. Initially, four different histological variants of PMTs were described: mixed connective tissue variant (PMTMCT), osteoblastoma-like variant, nonossifying fibroma-like variant, and ossifying fibroma-like variant [20]. However, later on, Felpe et al. [21] demonstrated that almost all previously identified mesenchymal tumors would fall under the single category of PMTMCT, debating the previous notion of 4 different histological subtypes. Of all the immunohistochemical markers investigated so far, only 2 have been tested positive, smooth muscle actin and FGF23, in 10 and 70% of the cases, respectively [21]. Of note, only proliferating cells within the tumor were noted to stain for FGF23 [21]. Somatostatin receptors have also been consistently detected in TIO tumors [22]. Therefore, it has been suggested that a positive staining for both FGF23 and somatostatin receptors would be a sensitive test for PMTs, though probably not specific enough [22].

PMTMCT also manifests ultrastructural features of neuroendocrine tumors [23]. However, typical immunohistochemical markers of neurosecretory tumors including S-100, neuron-specific enolase, chromogranin, and synaptophysin have not been detected [13]. Perhaps, vimentin is the only neurosecretary marker that has consistently been noted positive [24]. Interestingly, there are reported instances of tumors with histopathological features consistent with PMTMCT, though not associated with the clinical syndrome of osteomalacia. These tumors are sometimes classified as nonphosphaturic variant [21, 25].

Although characteristically benign, malignant behavior and metastases have occasionally been reported [26, 27]. Similarly, there have been rare instances of locally aggressive lesions as well as multifocal lesions [18]. It is worth noting that, even in the case of metastasizing tumors, the histopathological appearance of the tumor tends to be benign. On the other hand, microscopic infiltration of the surrounding soft tissue is often noted in the margins of an otherwise benign-appearing lesion [18].

7. Pathogenesis

Overexpression of phosphate-regulating factors has been consistently implicated in the pathogenesis of tumor-induced osteomalacia. Among all, FGF23 has perhaps the most established role. FGF23 was identified as the culprit phosphaturic substance after mutations in FGF23 gene were recognized in the pathophysiology of ADHR [28]. FGF23 is physiologically produced by normal bone cells [29] and, aside from its phosphaturic action, is thought to act directly on the bone and suppress differentiation of osteoblasts [30]. There is some evidence that the phosphaturic effect of FGF23 is somewhat PTH dependent. The notion is supported by the observation that in the presence of low to undetectable PTH levels, as occurs in hypoparathyroidism, FGF23 does not lead to hypophosphatemia [31].

To date, several other phosphate-regulating factors including matrix extracellular phosphoglycoprotein (MEPE) [30], secreted frizzled related protein-4 (sFRP-4) [32], and dentin matrix protein 1 (DMP1) [33] have been identified. However, their precise pathogenicity remains to be elucidated. Of note, despite a strong expression of messenger ribonucleic acid (mRNA) of the aforementioned factors by tumor cells, elevated plasma levels have not yet been reported in the setting of TIO. More recently, Lee et al. [34] identified a fibronectin 1–fibroblast growth factor receptor 1, FN1–FGFR1, fusion in 42% of the studied phosphaturic mesenchymal tumors (21/50). Additionally, a novel FN1–FGF1 fusion gene was reported in 6% of the cases (3/50) [34]. Lately, a case of TIO with elevated venous levels of both FGF7 and FGF23 has been reported, suggesting a possible phosphaturic role for FGF7 as well [35]. The phosphate-regulating factors act primarily on the proximal renal tubules, causing redistribution of sodium phosphate cotransporters and therefore impairing reabsorption of phosphate [36]. Moreover, as a secondary mechanism, FGF23 and sFRP-4 decrease


Table 1: Differential diagnoses of hypophosphatemia.

| Decreased absorption                              | Increased excretion                                      | Intercellular shifts                             |
|--------------------------------------------------|--------------------------------------------------------|--------------------------------------------------|
| Poor dietary intake                              | Hyperparathyroidism: primary and secondary              | Insulin effect, i.e., during refeeding syndrome   |
| Inhibition of absorption due to medications      | Hereditary hypophosphatemic rickets: XLHR (mutations in| Respiratory alkalosis                            |
| (including phosphate phosphatase regulatory genes) | ADHR (mutations in FGF23 gene), ARHR (mutations in     |                                                  |
|                                                  | DMP1 gene), HHRH (mutations in sodium phosphate        |                                                  |
|                                                  | transporter 2c)                                         |                                                  |
| Malabsorption syndromes, i.e., celiac disease,   | Fanconi syndrome: inherited versus acquired, i.e., heavy| Hungry bone syndrome                             |
| Crohn’s, nontropical sprue, etc.                  | metal induced, chemotherapeutic agents, monoclonal      |                                                  |
| Vitamin D deficiency or resistance: dietary,    | gammapathies, etc.                                     |                                                  |
| lack of sunlight, excess fluoride, etc.           | Tumor-induced osteomalacia                              | Increased metabolism: blast crisis, thyrotoxicosis|

FGF23, fibroblast growth factor 23; XLHR, X-linked hypophosphatemic rickets; ADHR, autosomal dominant hypophosphatemic rickets; ARHR, autosomal recessive hypophosphatemic rickets; HHRH, hereditary hypophosphatemic rickets with hypercalcemia.

Table 2: Laboratory tests recommended in cases of suspected TIO.

| Serum phosphorus | Serum calcium | 25-Hydroxyvitamin D | 1,25-Dihydroxyvitamin D | Parathyroid hormone | Alkaline phosphatase (bone-specific if available) | 24-hour urine collection for phosphorus, calcium, and creatinine | Fibroblast growth factor 23 | Serum protein electrophoresis and immunofixation | Urine monoclonal proteins, kappa and lambda chains |
|------------------|--------------|--------------------|------------------------|--------------------|-----------------------------------------------|-------------------------------------------------------------|-----------------------|-----------------------------------------------|-----------------------------------------------|

8. Diagnosis

Diagnosis of TIO should always be suspected in case of hypophosphatemia and excessive phosphaturia. Some of the notable causes of hypophosphatemia are listed in Table 1. A thorough history including family history of genetic phosphate abnormalities along with a complete biochemical testing is recommended as the next step (Table 2). A typical patient with TIO manifests low serum phosphate, normal to low calcium, normal PTH, normal 25-hydroxyvitamin D, elevated bone al-

cate phosphatase, and high FGF23 levels.
imaging with 1-2-year interval may be a reasonable course of action. Once the tumor is localized and resected, microscopic evaluation of the lesion allows for an accurate diagnosis of the PMT. FGF23 expression can be confirmed by the reverse transcription polymerase chain reaction (RT-PCR) technique on the tissue and also by anti-FGF23 antibodies which are still not widely available [48]. It is worth noting that the exquisite sensitivity of the molecular method in detection of FGF23 may lead to false-positive results in the case of non-phosphaturic mesenchymal tumors producing trace amounts of FGF23 including fibrous dysplasia, chondromyxoid fibroma [29], and aneurysmal bone cyst [49].

9. Management

Resection of the tumor is the ultimate definitive treatment of tumor-induced osteomalacia. Maintaining a wide surgical margin cannot be emphasized enough to prevent the recurrence of the tumor which has been reported in several instances [27]. A 10 mm margin for extremity lesions and 5 mm for trunk lesions have been proposed. Since FGF23 has a short half-life of 45–58 minutes [50], a rapid resolution of symptoms upon surgical removal is expected.

Surgical cure is evidenced by normalization of the serum biochemical abnormalities including serum phosphate level. It is important to note that reversal of phosphate levels after surgical resection is required to confirm the diagnosis of TIO [13]. Late recurrence happens in a small percentage of patients [21, 27]; therefore, long-term follow-up is warranted after the surgery. Should metastasis occur, the lung is the most common site [21, 25–27]. In a review of 32 Japanese cases of PMT/MCT, metastases were found in 4 patients (12.5%) on follow-up and 2 patients eventually died of the disease [25]. Radiofrequency ablation (RFA) has also received attention as a possible treatment modality which still needs further investigation [51]. Adjuvant radiotherapy, even though not well studied, has been recommended in cases of recurrence where repeat surgery would lead to significant disability such as losing a limb. Positive margins after surgery may also justify the use of postoperative radiotherapy.

If the tumor cannot be localized or surgically removed, medical therapy is recommended with phosphate supplementation and calcitriol [32]. The typical treatment regimen would be 15–60 mg/kg per day of elemental phosphate divided into 4–6 doses for 1–3 days. Calcitriol is given at 15–60 mg/kg per day, with a usual starting dose of 1.5 mg/day for an adult. Cinacalcet, an agonist of calcium-sensing receptors, has also led to promising outcomes, by lowering blood parathormone levels. Geller et al. [31] observed a significant bone-healing effect following treatment of two cases of TIO with 30 mg/day cinacalcet. Of note, despite the presence of somatostatin receptors on the cell surface of phosphaturic mesenchymal tumors, octreotide has not demonstrated significant clinical success [52].

Interestingly, the results of a phase I clinical trial on efficacy of a humanized anti-FGF23 antibody in adults with X-linked hypophosphatemic rickets (XLHR) indicated the safety and effectiveness of this novel treatment [53]. Given the similarity of pathogenesis, this antibody might be of therapeutic value for TIO as well.

10. Conclusion and Future Direction

In conclusion, TIO is a rare paraneoplastic syndrome caused by release of phosphate- and vitamin D-regulating mediators, most notably FGF23, from tumor cells. A distinct category of tumors, phosphaturic mesenchymal tumors, is responsible for majority of the cases. Excision of the culprit neoplasm is usually curative. Although these tumors are small and hard to locate on physical exam, a stepwise diagnostic approach involving functional and anatomical imaging studies and, if needed, selective venous sampling or aspiration of the lesion tends to be successful. Resection of the tumor is typically followed by a rapid decline in FGF23 levels and resolution of symptoms. Although characteristically benign, PMTs with aggressive features such as local invasion, metastasis, and late recurrence have also been described. When the tumor cannot be identified or resected, medical treatment with phosphate supplements, calcitriol, and cinacalcet is recommended.

Various aspects of TIO, ranging from pathogenesis to treatment, are yet to be understood. In terms of pathogenesis, the phosphaturic role of FGF7, which has recently been proposed, needs to be further elaborated in the future studies. From a diagnostic point of view, comparison between emerging modalities including somatostatin receptor PET tracers and more traditional imaging techniques such as MRI and PET/CT warrants further investigation. Finally, humanized anti-FGF23 antibody as a potential medical treatment for TIO is an area that is certainly worth exploring.

Disclosure

The authors would like to declare that this manuscript was presented as a poster at Allegheny Health Network’s Internal Medicine Research Day in May 2016 and won the first prize in the clinical vignette category.

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgments

The authors would like to thank Dr. David Hicks and Dr. Jinhong Li for their kind help with procurement of high-quality pathology images and their expert interpretation.

References

[1] R. Kumar, A. L. Folpe, and B. P. Mullan, “Tumor-induced osteomalacia,” *Translational Endocrinology and Metabolism*, vol. 7, no. 3, 2015.
[2] S. Fukimoto and T. Yamashita, “FGF23 is a hormone-regulating phosphate metabolism—unique biological characteristics of FGF23,” *Bone*, vol. 40, no. 5, pp. 1190–1195, 2007.
[3] K. B. Jonsson, R. Zahradnik, T. Larsson et al., “Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked
hypophosphatemia," New England Journal of Medicine, vol. 348, no. 17, pp. 1656–1663, 2003.

[4] R. A. McCance, "Osteomalacia with Looser’s nodes (Milkman’s syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years," Quarterly Journal of Medicine, vol. 16, no. 1, pp. 33–46, 1947.

[5] F. Albright, A. M. Butler, and E. Bloomberg, "Rickets resistant to vitamin D therapy," American Journal of Diseases of Children, vol. 54, no. 3, pp. 529–547, 1937.

[6] A. Prader, R. Illig, E. Uehlinger, and G. Stalder, "Rickets following bone tumor," Helvetica Paediatrica Acta, vol. 14, pp. 554–565, 1959.

[7] D. J. Evans and J. G. Azzopardi, "Distinctive tumours of bone and soft tissue causing acquired vitamin-D-resistant osteomalacia," Lancet, vol. 299, no. 7746, pp. 353–354, 1972.

[8] N. Weidner and D. Santa Cruz, "Phosphaturic mesenchymal tumors: A polymorphous group causing osteomalacia or rickets," Cancer, vol. 59, no. 8, pp. 1442–1454, 1987.

[9] V. Y. Jo and C. D. M. Fletcher, "WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition," Pathology, vol. 46, no. 2, pp. 95–104, 2014.

[10] H. Qari, A. Hamao-Sakamoto, C. Fuselier, Y. S. Cheng, H. Kessler, and J. Wright, "Phosphaturic mesenchymal tumor: 2 new oral cases and review of 53 cases in the head and neck," Head and Neck Pathology, vol. 10, no. 2, pp. 192–200, 2016.

[11] W. H. Chong, S. Yavuz, S. M. Patel, C. C. Chen, and M. T. Collins, "The importance of whole body imaging in tumor-induced osteomalacia," Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 12, p. 3599, 2011.

[12] M. K. Drezner, "Tumor-induced osteomalacia," Reviews in Endocrine and Metabolic Disorders, vol. 2, no. 2, pp. 175–186, 2001.

[13] W. H. Chong, A. A. Molinolo, C. C. Chen, and M. T. Collins, "Tumor-induced osteomalacia," Endocrine-Related Cancer, vol. 18, no. 3, pp. R53–R77, 2011.

[14] V. Jagtap, V. Sarathi, A. R. Lila et al., "Tumor-induced os- tomalacia: a single center experience," Endocrine Practice, vol. 17, no. 2, pp. 177–184, 2011.

[15] D. E. Leaf, R. C. Pereira, H. Bazari, and H. Jüppner, "Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma," Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 3, pp. 887–891, 2013.

[16] H.-A. Lin, S.-R. Shih, Y.-T. Tseng et al., "Ovarian cancer-related hypophosphatemic osteomalacia—a case report," Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 12, pp. 4603–4607, 2014.

[17] J. Dadonie, M. Miglinas, D. Mittiniene et al., "Tumour-induced osteomalacia: a literature review and a case report," World Journal of Surgical Oncology, vol. 14, no. 1, p. 4, 2016.

[18] M. Higley, B. Beckett, S. Schmahmann, E. Dacey, and E. Foss, "Locally aggressive and multifocal phosphaturic mesenchymal tumors: two unusual cases of tumor-induced osteomalacia," Skeletal Radiology, vol. 44, no. 12, pp. 1825–1831, 2015.

[19] S. Tajima and M. Fukayama, "Possibility of D2-40 as a diagnostic and tumor differentiation-suggestive marker for some of phosphaturic mesenchymal tumors," International Journal of Clinical and Experimental Pathology, vol. 8, no. 8, p. 9390, 2015.

[20] N. Weidner, "Review and update: oncogenic osteomalacia-rickets," Ultrastructural Pathology, vol. 15, no. 4-5, pp. 317–333, 1991.

[21] A. L. Folpe, J. C. Fanburg-Smith, S. D. Billings et al., "Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature," American Journal of Surgical Pathology, vol. 28, no. 1, pp. I-30, 2004.

[22] M. Houna, A. Clarkson, L. Sisson et al., "Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A)," Human Pathology, vol. 44, no. 12, pp. 2711–2718, 2013.

[23] G. E. Wilkins, S. Granleece, R. G. Hegele, J. Holden, D. W. Anderson, and G. P. Bondy, "Oncogenic osteomalacia: evidence for a humoral phosphaturic factor," Journal of Clinical Endocrinology & Metabolism, vol. 80, no. 5, pp. 1628–1634, 1995.

[24] A. Angeles-Angeles, A. Reza-Albarrán, F. Chable-Montero, J. C. Cordova-Ramón, J. Albores-Saavedra, and B. Martinez-Benitez, "Phosphaturic mesenchymal tumors. Survey of 8 cases from a single Mexican medical institution," Annals of Diagnostic Pathology, vol. 19, no. 6, pp. 375–380, 2015.

[25] R. Honda, Y. Kawabata, S. Ito, and F. Kikuchi, "Phosphaturic mesenchymal tumor, mixed connective tissue type, non-phosphaturic variant: report of a case and review of 32 cases from the Japanese published work," Journal of Dermatology, vol. 41, no. 9, pp. 845–849, 2014.

[26] T. Morimoto, S. Takenaka, N. Hashimoto, N. Araki, A. Myoui, and H. Yoshikawa, "Malignant phosphaturic mesenchymal tumor of the pelvis: a report of two cases," Oncology Letters, vol. 8, no. 1, pp. 67–71, 2014.

[27] A. Ogose, T. Hotta, I. Emura et al., "Recurrent malignant variant of phosphaturic mesenchymal tumor with oncogenic osteomalacia," Skeletal Radiology, vol. 30, no. 2, pp. 99–103, 2001.

[28] M. J. Econs and M. K. Drezner, "Tumor-induced osteomalacia—unveiling a new hormone," New England Journal of Medicine, vol. 330, no. 23, pp. 1679–1681, 1994.

[29] M. Riminucci, M. T. Collins, N. S. Fedarko et al., "FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting," The Journal of Clinical Investigation, vol. 112, no. 5, pp. 683–692, 2003.

[30] Y. Imanishi, J. Hashimoto, W. Ando et al., "Matrix extracellular phosphoglycoprotein is expressed in causative tumors of oncogenic osteomalacia," Journal of Bone and Mineral Metabolism, vol. 30, no. 1, pp. 93–99, 2012.

[31] J. L. Geller, A. Khorovar, M. H. Kelly, M. Riminucci, J. S. Adams, and M. T. Collins, "Cinacalcet in the management of tumor-induced osteomalacia," Journal of Bone and Mineral Research, vol. 22, no. 6, pp. 931–937, 2007.

[32] T. Berndt, T. A. Craig, A. E. Bowe et al., "Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent," Journal of Clinical Investigation, vol. 112, no. 5, pp. 785–794, 2003.

[33] S. Toyosawa, Y. Tomita, M. Kishino et al., "Expression of dentin matrix protein 1 in tumors causing oncogenic osteomalacia," Modern Pathology, vol. 17, no. 5, pp. 573–578, 2004.

[34] J.-C. Lee, S. Y. Su, C. A. Changou et al., "Characterization of FN1–FGFR1 and novel FN1–FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors," Modern Pathology, vol. 29, no. 11, pp. 1335–1346, 2016.

[35] S. Bansal, K. Khazim, R. Suri, D. Martin, S. Werner, and P. Fanti, "Tumor induced osteomalacia: associated with elevated circulating levels of fibroblast growth factor-7 in addition to fibroblast growth factor-23," Clinical Nephrology, vol. 85, no. 1, pp. 57–62, 2016.
[36] T. Shimada, M. Kakitani, Y. Yamazaki et al., “Targeted ablation of FGF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism,” *Journal of Clinical Investigation*, vol. 113, no. 4, pp. 561–568, 2004.

[37] J.-L. Dupond, H. Mahammedi, N. Magy, O. Blagosklonov, N. Meaux-Raault, and B. Kantelip, “Detection of a mesenchymal tumor responsible for hypophosphatemic osteomalacia using FDG-PET,” *European Journal of Internal Medicine*, vol. 16, no. 6, pp. 445–446, 2005.

[38] M. Duet, S. Kerkeni, R. Sfar, C. Bazille, F. Lioté, and P. Orcel, “Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia,” *Clinical Nuclear Medicine*, vol. 33, no. 11, pp. 752–756, 2008.

[39] Y. Kaneuchi, M. Hakozaki, R. Sfar, C. Bazille, F. Lioté, and P. Orcel, “Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia,” *Clinical Nuclear Medicine*, vol. 33, no. 11, pp. 752–756, 2008.

[40] C. A. García and R. P. Spencer, “Bone and In-111 octreotide imaging in oncogenic osteomalacia: a case report,” *Clinical Nuclear Medicine*, vol. 27, no. 8, pp. 582–583, 2002.

[41] C. von Falck, T. Rodt, H. Rosenthal et al., “68Ga-DOTANOC PET/CT for the detection of a mesenchymal tumor causing oncogenic osteomalacia,” *European Journal of Nuclear Medicine and Molecular Imaging*, vol. 35, no. 5, p. 1034, 2008.

[42] K. Agrawal, S. Bhadada, B. R. Mittal et al., “Comparison of 18F-FDG and 68Ga DOTATATE PET/CT in localization of tumor causing oncogenic osteomalacia,” *Clinical Nuclear Medicine*, vol. 40, no. 1, pp. e6–e10, 2015.

[43] D. Wild, H. R. Mäcke, B. Waser et al., “68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5,” *European Journal of Nuclear Medicine and Molecular Imaging*, vol. 32, no. 6, p. 724, 2005.

[44] S. Breer, T. Brunkhorst, F. T. Beil et al., “68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT,” *Bone*, vol. 64, pp. 222–227, 2014.

[45] A. M. Dissanayake, J. L. Wilson, I. M. Holdaway, and I. R. Reid, “Oncogenic osteomalacia: culprit tumor detection whole body magnetic resonance imaging,” *Internal Medicine Journal*, vol. 33, no. 12, pp. 615–616, 2003.

[46] P. Andreopoulou, C. E. Dumitrescu, M. H. Kelly et al., “Selective venous catheterization for the localization of phosphaturic mesenchymal tumors,” *Journal of Bone and Mineral Research*, vol. 26, no. 6, pp. 1295–1302, 2011.

[47] D. M. Scuibba, R. J. Petteys, S. F. Shakur et al., “En bloc spondylectomy for treatment of tumor-induced osteomalacia: case report,” *Journal of Neurosurgery: Spine*, vol. 11, no. 5, pp. 600–604, 2009.

[48] A. Bahrami, S. W. Weiss, E. Montgomery et al., “RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia,” *American Journal of Surgical Pathology*, vol. 33, no. 9, pp. 1348–1354, 2009.

[49] S. Krishnamurthy, C. Y. Inwards, A. M. Oliveira, and A. L. Folpe, “Frequent expression of fibroblast growth factor-23 (FGF-23) mRNA in aneurysmal bone cyst (ABC),” in *Laboratory Investigation*, Nature Publishing Group, New York, NY, USA, 2011.

[50] A. Khosravi, C. M. Cutler, M. H. Kelly et al., “Determination of the elimination half-life of fibroblast growth factor-23,” *Journal of Clinical Endocrinology & Metabolism*, vol. 92, no. 6, pp. 2374–2377, 2007.

[51] E. Hesse, H. Rosenthal, and L. Bastian, “Radiofrequency ablation of a tumor causing oncogenic osteomalacia,” *New England Journal of Medicine*, vol. 357, no. 4, pp. 422–424, 2007.

[52] F. Paglia, S. Dionisi, and S. Minisola, “Octreotide for tumor-induced osteomalacia,” *New England Journal of Medicine*, vol. 346, no. 22, pp. 1748-1749, 2002.

[53] T. O. Carpenter, E. A. Imel, M. D. Ruppe et al., “Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia,” *Journal of Clinical Investigation*, vol. 124, no. 4, pp. 1587–1597, 2014.